GLP-1 Analog Modulates Appetite, Taste Preference, Gut Hormones and Regional Body Fat Stores in Adults with Obesity.
Obesity is associated with alterations in appetite, gastrointestinal (GI) hormone levels and excessive fat mass. We previously published a double-blind, placebo-controlled, randomized, 16-week trial on effects of once daily GLP-1 analog, liraglutide on weight, satiation, and gastric functions in obese volunteers. The aim of this sub-study was to compare to placebo the effects of liraglutide on appetite, taste preference, regional body fat stores and anthropometric measurements. Forty obese adults received standard instruction for weight management, monthly behavioral intervention utilizing motivational interviews, and 16-week treatment of once daily liraglutide (escalated to 3mg SQ daily). At baseline and 16 weeks, the following were measured: appetite and taste preferences rated every 30 minutes for 5 hours after ingesting 300mL Ensure®; maximal tolerated volume (MTV) with a nutrient drink test; fasting and postprandial bioactive GLP-1 (7-36) and PYY levels; total and regional body fat with dual-energy x-ray absorptiometry (DXA), and waist and hip circumference. Thirty-five participants (17 liraglutide; 18 placebo) completed the trial. Compared to placebo group, liraglutide group had significant reductions in MTV, prospective food consumption score, desire to eat something sweet, salty, savory or fatty, and an increase in perceived fullness. Postprandial plasma levels of GLP-1 decreased and PYY levels increased with liraglutide relative to baseline. Significant reductions in total body, trunk, upper and lower body fat without reduction in lean body mass were observed. Liraglutide 3mg SQ modulates appetite, taste preference, gut hormones and regional body fat stores in adults with obesity without reduction in lean body mass.